

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 24 NO 4 DEC 2007

ISSN 0790-9667



'Winter motif' by JK. Acrylics on board (16" x 20")

Zzzzzzzzz Zopitan

7.5 mg and convenient 3.75mg tablets available
ZOPICLONE

...when Sleepless Nights
are hard to BEAR.

Convenient
3.75mg
tablets available
RAPIDLY ABSORBED*

ABBREVIATED PRESCRIBING INFORMATION

Zopitan 3.75 mg & 7.5 mg Tablets

Presentation: The 3.75 mg tablet is an orange, round, film-coated tablet with ZOC 3.75 on one side. The 7.5 mg tablet is a white, round, film-coated tablet, with ZOC 7.5 on one side and scored on both sides. Each tablet contains 3.75 mg or 7.5 mg zopiclone. **Indications:** Short term treatment of insomnia. **Dosage:** The recommended dose for adults is 7.5 mg. Treatment of the elderly and patients with impaired liver function, chronic respiratory insufficiency or impaired renal function should be started on 3.75 mg. Zopitan should be taken just before retiring for the night. **Contraindications:** Myasthenia gravis, hypersensitivity to zopiclone, severe respiratory insufficiency, sleep apnoea syndrome, severe hepatic insufficiency, use in children. **Warnings and precautions:** There is an absence of any marked tolerance for treatment periods up to 4 weeks. May lead to physical and psychic dependence. Abrupt termination of treatment may result in withdrawal or rebound phenomena, therefore it is recommended that the dosage is decreased gradually. The duration of treatment should be as short as possible and should not exceed 4 weeks for insomnia. Benzodiazepines may induce anterograde amnesia. Reactions like restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses and inappropriate behaviour are known to occur when using benzodiazepines; should these occur, the drug should be discontinued. The elderly and patients with chronic respiratory insufficiency should be given a reduced dose. Not recommended in severe hepatic insufficiency or primary psychotic illness. Benzodiazepines should not be used alone to treat depression or anxiety associated with depression. Should be used with extreme caution in patients with a history of alcohol or drug abuse. Do not drive or operate machinery until it is established that performance is not impaired. Contains lactose. **Interactions:** The sedative effect may be enhanced by alcohol. Concomitant use with antipsychotics, hypnotics, anxiolytics, sedatives, antidepressants, narcotic analgesics, anti-epileptic drugs, anaesthetics, sedative antihistamines, Erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, rifampicin, carbamazepine, phenobarbital, phenytoin, St John's wort. **Pregnancy and lactation:** Not recommended. **Undesirable effects:** Most common: Bitter taste, drowsiness, numb emotions, reduced alertness, confusion, fatigue, headache, dizziness, muscle weakness, ataxia, double vision. **Pack size:** 28 tablets in blister packs. **Marketing authorisation holder:** Clonmel Healthcare Ltd, Waterford Road, Clonmel, Co. Tipperary, Tel: 052 77777

Marketing authorisation numbers: PA 126 104 1-2. Full prescribing information is available on request. *Ref: Summary of Product Characteristics.

ZOPITAN IS THE
CLONMEL BRAND
OF ZOPICLONE.

ch
CLONMEL
HEALTHCARE

Editor-in-Chief: Brian A Lawlor,
Professor of Old Age Psychiatry,
St Patrick's Hospital, Dublin 8

Trainee Editor: Brendan D Kelly,
Consultant Psychiatrist, Department of
Adult Psychiatry, The Mater
Misericordiae Hospital, Dublin 7

Production Editors:
Anne Henrichsen, Sonja Storm

Advertising Manager:
Deirdre Gleeson

Administrator: Andrea McAdam

Founding Editor: Mark Hartman

Associate Editor: Ted Dinan (Cork)

Editorial Board: Patricia Casey
(Dublin), Anthony Clare (Dublin),
Stephen Cooper (Belfast),
Michael Fitzgerald (Dublin),
Brian Leonard (Galway),
Roy McClelland (Belfast),
Eadbhard O'Callaghan (Dublin),
Brian O'Shea (Wicklow), Ian Pullen
(Edinburgh), Philip Snaith (Leeds),
John Waddington (Dublin),
Richard Williams (Victoria)

Statistical Editor:
Ronan Conroy (Dublin)

Submissions & correspondence to:
The Editor,
Irish Journal of Psychological Medicine,
25 Adelaide Street, Dun Laoghaire,
Co Dublin, Ireland.

Telephone: 00-353-1-2803967

Fax: 00-353-1-2807076

Email: psychological@medmedia.ie

Website: www.ijpm.org

Publisher 
MedMedia Ltd,
25 Adelaide Street,
Dun Laoghaire, Co Dublin, Ireland.
www.medmedia.ie

Printing: W&G Baird Ltd

Subscriptions

Rates per volume of four issues
(Mar, Jun, Sept, Dec): €155
Incl. airmail postage internationally.

**Subscription enquiries, orders
and cheques made payable to:**
MedMedia Ltd,
25 Adelaide St, Dun Laoghaire,
Co Dublin, Ireland
Tel: + 353 1 280 3967
Email: psychological@medmedia.ie
www.medmedia.ie

Circulation

2,200 to 54 countries. The Journal
participates in the World Health
Organisation project to improve
distribution of scientific materials on
mental health. Publication does not
imply endorsement. Limited photo-
copying authorisation granted for a fee
to Copyright Clearance Center,
27 Congress Street, Salem, MA 01970,
USA, or to appropriate Reproduction
Rights Organisation; isolated non-profit,
academic photocopying excepted.

Editorial

127 Professor Anthony Clare: an appreciation of his contribution to psychiatry

Brian Lawlor, Marcus Webb, Ted Dinan

129 The future of post-graduate training in psychiatry in Ireland: an address to the Irish Psychiatric Training

Anthony Clare

Original Papers

132 First admissions to inpatient care in Ireland for schizophrenia 1971-2004: trends in age and gender

Caroline Hart, Donna T Doherty, Dermot Walsh

139 Psychological health and well-being among young Irish adults

Anne Cleary, Elizabeth Nixon, Michael Fitzgerald

Brief Report

145 Toxic psychosis? Duration of untreated psychosis, symptomatology and cognitive deterioration in first episode psychosis

Richard Lawoyin, Keith Gaynor, Barbara Dooley, Elizabeth Lawlor, Mary Clarke, Eadbhard O'Callaghan

Historical

149 Care of the mentally ill in Ireland in 1901 – the vindication of a policy

Dermot Walsh

Reviews

156 Depression and cardiovascular disease: does antidepressant treatment improve cardiac outcome?

Damien Gallagher

Case reports

159 Bilateral globus pallidus deep brain stimulators for a case of severe neuroleptic-induced dystonia and dyskinesia

Stephen McWilliams, Nick de Pennington, Tipu Z Aziz, Justin Brophy

142a John Dunne Medal

161 Letters to the Editor

162 Book Reviews

164a Guidelines for Authors

165 Index to Key words 2007

166 Index to Authors 2007

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from **University Microfilms International**, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the **Adonis** service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in **Ulrich's International Periodicals Directory** (**Bowker** International Serials Database), **EBSCO's** Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

THIS IS MY SON BRIAN

We see much more of
each other now.
It's good to
have him
back...

 **Seroquel**
quetiapine

HELPS MAKE LIVING A REALITY...

Seroquel has proven efficacy in the treatment of a broad range of symptoms in schizophrenia including agitation and hostility^{1,2,3}, and has been proven to reduce mania symptoms in bipolar disorder as early as day 4⁴.

Seroquel® Abridged prescribing information

(For full details see summary of product characteristics) **Presentations:** Film coated tablets containing 25mg, 100mg, 200mg and 300mg of quetiapine (as quetiapine fumarate). **Uses:** Treatment of schizophrenia and moderate to severe manic episode. **Dosage and Administration: Schizophrenia: Adults:** Initial titration from 50mg to 300mg over first 4 days. From day 4 onwards the dose should be titrated to the usual effective dose of 300-450 mg/day. Dose range 150 to 750 mg/day. **Bipolar disorder (Manic episodes): Adults:** Initial titration from 100mg to 400mg over first 4 days. Dose range: 200-800 mg/day. **Elderly:** Rate of dose titration may need to be slower and daily therapeutic dose lower than in younger patients. **Children & Adolescents:** Not evaluated. **Renal Impairment:** No dose adjustment required. **Hepatic Impairment:** Use with caution. Patients should be started on 25 mg/day and increased by 25 - 50 mg/day until an effective dosage is achieved. **Contra-indications:** Hypersensitivity to quetiapine fumarate or excipients. Concomitant administration of cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors,azole-antifungal agents, erythromycin, clarithromycin and nefazodone. **Precautions and warnings:** Known cardiovascular disease, cerebrovascular disease, or other conditions predisposing to hypotension. Possible initial orthostatic hypotension during the dose titration period. Caution is recommended in patients with a history of seizures. If signs and symptoms of tardive dyskinesia appear dose reduction or discontinuation should be considered. In the event of neuroleptic malignant syndrome discontinue treatment and appropriate medical treatment given. Hyperglycaemia or exacerbation of pre-existing diabetes has been reported in very rare cases. QT prolongation was observed with overdose. As with other antipsychotics, caution should be exercised when quetiapine is prescribed in patients with cardiovascular disease or family history of QT prolongation, and when quetiapine is prescribed with medicines known to increase QTc interval and concomitant neuroleptics, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia. Acute withdrawal symptoms such as nausea, vomiting and insomnia have been described after abrupt cessation of antipsychotic drugs including Seroquel. Gradual withdrawal is advisable. Not approved for the treatment of patients with dementia - related psychosis. **Undesirable effects:** The most commonly reported Adverse Drug Reactions with Seroquel are somnolence, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension and dyspepsia. As with other antipsychotics, weight gain, syncope, neuroleptic malignant syndrome, leucopenia, neutropenia and peripheral oedema, have been associated with Seroquel. For full list of undesirable effects refer to SPC. **Interactions:** Use with caution with other centrally acting drugs and alcohol. CYP3A4 inhibitors such as ketoconazole are contraindicated. Grapefruit juice, phenytoin, carbamazepine, thioridazine. Observe caution when used concomitantly with drugs known to cause electrolyte imbalance or to increase QTc interval. **Pregnancy & lactation:** Safety and efficacy not established. **Effects on ability to drive:** Patients should be advised not to drive or operate machinery until individual susceptibility is known. **Pharmaceutical precautions:** Do not store above 30°C. **Legal category:** POM. **Product Authorisation Numbers:** Seroquel 25 PA970/18/1; Seroquel 100 PA970/18/2; Seroquel 200 PA970/18/3; Seroquel 300 PA970/18/7 **Product Authorisation holder:** AstraZeneca Ltd., Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU. **Further information on request from:** AstraZeneca Pharmaceuticals (Ireland) Limited, College Park House, 20 Nassau Street, Dublin 2. Tel. 01 609 7100; Fax: 01 679 6650. Abridged Prescribing Information prepared: August 2007. **Date of preparation:** December 2007.

References

1. Tandon R & Jibson MD. International Journal of Psych in Clinical Practice, 2005; 9(3):204-212
2. Hellewell et al. Seroquel: efficacy in aggression, hostility and low mood of schizophrenia. Poster presented at C.I.N.P. Glasgow, UK, 1998.
3. Arango & Bernardo. Hum Psychopharmacol, 2005; 20: 237-241.
4. Vieta E. et al. Current Medical Research and Opinion. 2005; 21: P1-P12.

 **AstraZeneca**
NEUROSCIENCE